(Q44006206)

English

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

scientific article published in June 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease (English)

1 reference

Europe PubMed Central

28 November 2017

0 references

Crohn's disease

1 reference

based on heuristic

inferred from title

author name string

Sabate JM

1

1 reference

Europe PubMed Central

28 November 2017

Villarejo J

2

1 reference

Europe PubMed Central

28 November 2017

Lemann M

3

1 reference

Europe PubMed Central

28 November 2017

Bonnet J

4

1 reference

Europe PubMed Central

28 November 2017

Allez M

5

1 reference

Europe PubMed Central

28 November 2017

Modigliani R

6

1 reference

Europe PubMed Central

28 November 2017

language of work or name

0 references

publication date

1 June 2002

1 reference

Europe PubMed Central

28 November 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

28 November 2017

16

1 reference

Europe PubMed Central

28 November 2017

1117-1124

1 reference

Europe PubMed Central

28 November 2017

6

1 reference

Europe PubMed Central

28 November 2017

Primary and recurrent Crohn's disease. Experience with 1379 patients

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Infliximab: a review of its use in the management of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalidomide: current and potential clinical applications

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Immunomodulation by thalidomide and thalidomide analogues

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01273.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2002.01273.X

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44006206&oldid=2105579484"